Literature DB >> 28969985

PML risk and natalizumab: the elephant in the room.

Tobias Derfuss1, Ludwig Kappos2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28969985     DOI: 10.1016/S1474-4422(17)30335-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  2 in total

1.  Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.

Authors:  Sandra Vukusic; Fabien Rollot; Romain Casey; Julie Pique; Romain Marignier; Guillaume Mathey; Gilles Edan; David Brassat; Aurélie Ruet; Jérôme De Sèze; Elisabeth Maillart; Hélène Zéphir; Pierre Labauge; Nathalie Derache; Christine Lebrun-Frenay; Thibault Moreau; Sandrine Wiertlewski; Eric Berger; Xavier Moisset; Audrey Rico-Lamy; Bruno Stankoff; Caroline Bensa; Eric Thouvenot; Olivier Heinzlef; Abdullatif Al-Khedr; Bertrand Bourre; Mathieu Vaillant; Philippe Cabre; Alexis Montcuquet; Abir Wahab; Jean-Philippe Camdessanché; Ayman Tourbah; Anne-Marie Guennoc; Karolina Hankiewicz; Ivania Patry; Chantal Nifle; Nicolas Maubeuge; Céline Labeyrie; Patrick Vermersch; David-Axel Laplaud
Journal:  JAMA Neurol       Date:  2020-01-01       Impact factor: 18.302

Review 2.  Non-Invasive Delivery of Therapeutics into the Brain: The Potential of Aptamers for Targeted Delivery.

Authors:  Bakhtiar Bukari; Rasika M Samarasinghe; Jinjutha Noibanchong; Sarah L Shigdar
Journal:  Biomedicines       Date:  2020-05-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.